Bank of New York Mellon
CADX

Bank of New York Mellon’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Bank of New York Mellon’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-311,910
Closed -$2.82M – 4273
2013
Q4 		$2.82M Sell
311,910
-19,530
-6% -$141K ﹤0.01% 2659
2013
Q3 		$2.09M Buy
331,440
+41,868
+14% +$266K ﹤0.01% 2828
2013
Q2 		$1.98M Buy
+289,572
New +$2.02M ﹤0.01% 2797

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Bank of New York Mellon's CADX Position: Q1 2014 in Review

Bank of New York Mellon sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 311,910 shares — an estimated $2.82M sold.

Bank of New York Mellon first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $2.82M in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • Bank of New York Mellon reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • Bank of New York Mellon sold 311,910 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $2.82M.
  • Bank of New York Mellon first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • Bank of New York Mellon's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $2.82M in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Bank of New York Mellon's 13F filing for Q1 2014, filed 14 May 2014.